Page 2 - Lab Abnormalities News Today

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses––Results presented in late-breaking oral session at the ESMO World Congress on Gastrointestinal Cancer–BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced full results from...

-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer - read this article along with other careers information, tips and advice on BioSpace

- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has been drastically affecting the daily lives of millions of people. COVID-19 is described as a multiorgan disease that affects not only the respiratory tract of infected individuals, but it has considerable effects on the musculoskeletal system, causing excessive fatigue, myalgia, arthralgia, muscle weakness and skeletal muscle damage. These symptoms can persist for months, decreasing the quality of life of numerous individuals. C...

– Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months of Follow-Up –BOTHELL, Wash.--(BUSINESS WIRE)--#SABCS2021--Seagen Inc. (Nasdaq:SGEN) today announced the presentation...

- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months

(0) - Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial - - Results Further Support TUKYSA as Well-Tolerated Treatment Option That Improves Survival in Patients with Previously Treated Metastatic HER2-Positive Breast Cancer With and Without Brain Metastases - Seagen Inc. (Nasdaq:SGEN) today announced that improvements in overall survival (OS) and progression-free survival ...

Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Share this article Share this article TOKYO and BOTHELL, Wash., Feb. 18, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:  Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV ® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEVs accelerated approv...